Seminars in Oncology
Volume 29, Issue 4 , Pages 382-388 , August 2002

European approach to adjuvant treatment of intermediate- and high-risk malignant melanoma

References 

  1. Veronesi U, Cascinelli N, Adamus J, et al.  Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med. 1988;318:1159–1162
  2. Cascinelli N. Update WHO-10 trial. In: WHO Program Meeting, Albany, NY, personal communication. May 1995;
  3. Banzet P, Thomas A, Vuillemin E, et al.  Wide versus narrow surgical excision in thin (<2 mm) stage I primary cutaneous malignant melanoma: Long term results of a French multicentric prospective randomized trial on 319 patients. Proc Am Assoc Clin Oncol. 1993;12:387; (abstr)
  4. Cohn-Cedermark G, Rutqvist LE, Andersson R, et al.  Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer. 2000;89:1495–1501
  5. Balch CM, Urist MM, Karakousis CP, et al.  Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg. 1993;218:262–267
  6. Balch CM, Soong SJ, Smith T, et al.  Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol. 2001;8:101–110
  7. Heaton KM, Sussman JJ, Gershenwald JE, et al.  Surgical margins and prognostic factors in patients with thick (>4 mm) primary melanoma. Ann Surg Oncol. 1998;5:322–328
  8. Ball AS, Thomas J. Surgical management of malignant melanoma. Br Med Bull. 1995;51:584–608
  9. Cady B. Lymph node metastases. Indicators, but not governors of survival. Arch Surg. 1984;119:1067–1072
  10. Veronesi U, Adamus J, Bandiera DC, et al.  Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med. 1977;297:627–630
  11. Sim FH. A prospective randomized study of the efficacy of routine elective lymphadenopathy in management of malignant melanoma; preliminary results. Cancer. 1985;41:948–951
  12. Balch CM, Soong SJ, Bartolucci AA, et al.  Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg. 1996;224:255–263
  13. Balch CM, Soong S, Ross MI, et al.  Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol. 2000;7:87–97
  14. Cascinelli N, Morabito A, Santinami M, et al.  Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: A randomised trial. WHO Melanoma Programme. Lancet. 1998;351:793–796
  15. Eggermont AMM. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping. Recent Results Cancer Res. 2000;157:178–189
  16. Ghussen F, Nagel K, Groth W, et al.  A prospective randomized study of regional extremity perfusion in patients with malignant melanoma. Ann Surg. 1984;200:764–768
  17. Schraffordt-Koops H, Vaglini M, Suciu S, et al.  Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593 J Clin Oncol. 1998;16:2906–2912
  18. Eggermont AMM, Schraffordt Koops H, Lienard D, et al.  Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: A multicenter trial. J Clin Oncol. 1996;14:2653–2665
  19. Eggermont AMM, ten Hagen TLM. Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives. Curr Oncol Rep. 2001;3:359–367
  20. Eggermont AMM. The current EORTC Melanoma Cooperative Group adjuvant trial program on malignant melanoma: Prognosis versus efficacy, toxicity and costs. Melanoma Res. 1997;7(suppl 2):S127–S131
  21. Morton DL, Eilber FR, Homes EC, et al.  Preliminary results of a randomised trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases. Aust NZ J Surg Clin Oncol. 1978;17:434a; (abstr)
  22. Hersey P, Coates A, McCarthy WH. Interim analysis of a randomized trial of immunotherapy with vaccinia melanoma cell lysates [VMCL] following surgical removal of high risk melanoma. Proc Am Assoc Cancer Res. 1996;37:489; (abstr)
  23. Wallack MK, Sivanandham M, Balch CM, et al.  Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: The final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg. 1998;187:69–77
  24. Sondak V, Liu PY, Kempf RA, et al.  SWOG-9035: Adjuvant therapy of intermediate-thickness node-negative melanoma with an allogeneic tumor vaccine. J Immunother. 2000;5:600; (abstr)
  25. Bystryn JC, Zeleniuch-Jaquotte A, Oratz R, et al.  Double–blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin Cancer Res. 2001;7:1837–1838
  26. Livingstone PO, Wong GYC, Adluri S, et al.  Improved survival in stage III melanoma patients with GM2 antibodies: A randomised trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol. 1994;12:1036–1044
  27. Sosman JA, Unger JM, Liu PY, et al.  Significant impact of HLA class I alleles on outcome in T3N0M0 melanoma patients treated with Melacine (MEL): An allogeneic cell lysate vaccine: Prospective analysis of Southwest Oncology Group (SWOG)-9035. Proc Am Soc Clin Oncol. 2001;20:351; (abstr)
  28. Kirkwood JM. Melanoma. In:  DeVita VT,  Hellman S,  Rosenberg SA editor. Biologic Therapy of Cancer: Principles and Practice. Phildelphia, PA: Lippincott; 1995;p. 388–411
  29. Slaton JW, Perrotte P, Inoue K, et al.  Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res. 1999;5:2726–2734
  30. Falkson CI, Falkson G, Falkson HC. Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic melagnant melanoma. J Clin Oncol. 1991;9:1403–1408
  31. Tomson DB, Adena M, McLeod GRC, et al.  Interferon-alpha 2a does not improve response or survival when combined with dacarbazide in metastatic malignant melanoma: Results of a multi-institutional Australian randomized trial. Melanoma Res. 1993;3:133–138
  32. Sparano JA, Fisher RI, Sunderland M, et al.  Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol. 1993;11:1969–1977
  33. Bajetta E, Di Leo A, Zampino MG, et al.  Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol. 1994;12:806–811
  34. Falkson CI, Ibrahim J, Kirkwood JM, et al.  Phase III trial of dacarbazine versus dacarbazide with interferon alpha2b versus dacarbazide with tamoxifen versus dacarbazide with interferon alpha2b wtih tamoxifen in patients with metastatic malignant melanoma: An Eastern Cooperative Oncology study. J Clin Oncol. 1998;16:1743–1751
  35. Dorval T, Negrier S, Chevreau C, et al.  Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: A Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study. Cancer. 1999;85:1060–1066
  36. Middleton MR, Lorigan P, Owen J, et al.  A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer. 2000;82:1158–1162
  37. Kirkwood J. Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;17:7–17
  38. Grob JJ, Dreno B, de la Salmoniere P, et al.  Randomized trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma Lancet. 1998;351:1905–1910
  39. Creagan ET, Dalton RJ, Ahmann DL, et al.  Randomized surgical adjuvant clinical trial or recombinant interferon-alfa-2a in selected patients with malignant melanoma. J Clin Oncol. 1995;13:2776–2783
  40. Kirkwood JM, Ibrahim JG. Sondak VK, et al: High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000;18:2444–2459
  41. Kirkwood JM, Manola J, Ibrahim JG, et al.  Pooled analysis of four ECOG-Intergroup trials of high-dose interferon alfa-2b (HDI) in 1916 patients with high-risk resected cutaneous melanoma. Proc Am Soc Clin Oncol. 2001;20:1395; (abstr)
  42. Kirkwood JM, Ibrahim JG, Sosman JA, et al.  High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001;19:2370–2380
  43. Cascinelli N, Bufalino R, Morabito A, et al.  Results of adjuvant interferon study in WHO melanoma programme. Lancet. 1994;343:913–914
  44. Cascinelli N, Belli F, MacKie RM, et al.  Effect of long-term adkivant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: A randomised trial. Lancet. 2001;358:866–869
  45. Cameron DA, Cornbleet MC, MacKie RM, et al.  Adjuvant interferon alpha in high risk melanoma: The Scottish study. Br J Cancer. 2001;84:1146–1149
  46. Eggermont AMM, Kleeberg UR, Ruiter DJ, et al.  The European Organization for Research and Treatment of Cancer Melanoma Group trial experience with more than 2000 patients, evaluating adjuvant therapy treatment with low or intermediate doses of interferon alpha-2b. In: American Society of Clinical Oncology 2001 Educational Book. Alexandria, VA: ASCO; 2001;p. 88–93
  47. Hancock BW, Wheatley K, Harrison G, et al.  Aim high-adjuvant interferon in melanoma (high risk), a United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) randomised study of observation versus adjuvant low dose extended duration interferon alfa-2a in high risk resected malignant melanoma. Proc Am Soc Clin Oncol. 2001;20:1393; (abstr)
  48. Pehamberger H, Soyer P, Steiner A, et al.  Adjuvant interferon a-2a treatment in resected primary stage II cutaneous melanoma. J Clin Oncol. 1998;16:1425–1429
  49. Groenewegen G, Osanto S, van der Rhee HJ, et al.  Interferon as an adjuvant treatment for melanoma; registered but not indicated. Ned Tijdschr Geneesk. 2000;144:2160–2161 (abstr)
  50. Singh RK, Gutman M, Bucana CD, et al.  Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA. 1995;92:4562–4566
  51. Wheatley K, Hancock B, Gore M, et al.  Interferon-α as adjuvant therapy for melanoma: A meta-analysis of the randomised trials. Proc Am Soc Clin Oncol. 2001;20:1394; (abstr)
  52. Eggermont AMM. Role of interferon–alpha in malignant melanoma remains to be determined. Eur J Cancer. 2001;37:2147–2153

☆ Address reprint requests to Alexander M.M. Eggermont, MD, PhD, Professor of Surgical Oncology, Department of Surgical Oncology, Erasmus University Medical Center–Daniel den Hoed Cancer Center, 301 Groene Hilledijk, 3075 EA Rotterdam, the Netherlands.

PII: S0093-7754(02)50268-2

doi: 10.1053/sonc.2002.34117

Seminars in Oncology
Volume 29, Issue 4 , Pages 382-388 , August 2002

Article Tools